Table 2.
Subgroup analyses in terms of overall survival, disease-free survival and Recurrence-free survival (adjusted HR).
| Characteristics | Overall survival | Disease-free survival | Recurrence-free survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | HR (95%CI) | P | Heterogeneity | n | HR (95%CI) | P | Heterogeneity | n | HR (95%CI) | P | Heterogeneity | |
| Anatomical classification of CC | 20 | 2.10 (1.72,2.56) | <0.001 | 58.70% | 3 | 2.52 (1.35,4.69) | 0.004 | 74.10% | 6 | 2.33 (1.93,2.82) | <0.001 | 0.00% |
| Intrahepatic CC | 9 | 2.19 (1.70,2.82) | 0.015 | 43.80% | 2 | 3.45 (2.23,5.34) | <0.001 | 0.00% | ||||
| Perihilar CC | 3 | 1.45 (1.08,1.96) | <0.001 | 14.70% | 1 | NA | NA | NA | ||||
| Distal CC | 5 | 2.43 (1.33,4.44) | 0.004 | 77.70% | ||||||||
| Different CC | 3 | 2.38 (1.28,4.45) | 0.006 | 55.10% | ||||||||
| Ethnicity | ||||||||||||
| Asian | 15 | 2.19 (1.72,2.80) | <0.001 | 63.40% | ||||||||
| Caucasian | 5 | 1.87 (1.31,2.66) | 0.001 | 45.40% | ||||||||
| Test for sarcopenia | ||||||||||||
| PMI | 12 | 2.18 (1.64,2.89) | <0.001 | 59.20% | 4 | 2.29 (1.76,2.99) | <0.001 | 20.40% | ||||
| SMI | 8 | 2.05 (1.51,2.77) | <0.001 | 63.10% | 2 | 2.38 (1.82,3.10) | <0.001 | 0.00% | ||||
| Adjuvant chemotherapy | ||||||||||||
| Yes | 2 | 2.99 (1.72,5.21) | <0.001 | 0.00% | ||||||||
| No | 6 | 2.04 (1.43,2.89) | <0.001 | 67.50% | ||||||||
| Any | 12 | 2.08 (1.58,2.74) | <0.001 | 59.70% | ||||||||
CC, cholangiocarcinoma; PMI, Psoas Muscle Index; SMI, Skeletal Muscle Index; NA, not applicable.